logo-loader
viewScancell Holdings PLC

Scancell Holdings appoints new independent director

Dr Ursula Ney joins the immunotherapies specialist with immediate effect, replacing Dr Matthew Frohn who stands down from end October

Scancell Holdings PLC -
Ney was a director at UK biotech pioneers Celltech and Antisoma and spent her early career with Sandoz and Roche

Scancell Holdings PLC (LON:SCLP) has appointed a new independent director with 30 years’ experience in the life sciences sector.

Dr Ursula Ney joins the immunotherapies specialist with immediate effect, replacing Dr Matthew Frohn, who is standing down at the end of the month.

Ney was a director at UK biotech pioneers Celltech and Antisoma and spent her early career with Sandoz and Roche.

Most recently, she was chief executive of French drug developer Genkyotex and is currently a non-executive director of Proteome Sciences.

“Ursula’s extensive late-stage development experience in the biotech sector will be invaluable as the company continues to develop its product pipeline,” said Scancell chairman, Dr John Chiplin.

“I’d also like to take this opportunity to thank Matthew Frohn for the invaluable contributions he has made to the company since he was first appointed to the Board in 2006. We wish him well in his future endeavours.”

Quick facts: Scancell Holdings PLC

Price: 5.1 GBX

LSE:SCLP
Market: LSE
Market Cap: £23.73 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Scancell Holdings PLC named herein, including the promotion by the Company of Scancell Holdings PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Scancell to raise up to £8mln to develop its three main drug candidates

Cliff Holloway, chief executive at Scancell Holdings Plc (LONSCLP), tells Proactive Investors they're raising up to £8mln through a placing and open offer – cash that will be used develop their three main drug candidates. A placing and subscription at 12 pence a share will account for...

on 18/4/18

2 min read